2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2942

Dyadic Study of Partner Social Support for Physical Activity and Its Role in the Initiation and Maintenance of Increased Physical Activity Among Insufficiently Active People with Hip/Knee Osteoarthritis
Abstract Number: 2943

Helping a Non-Urban Community Walk with Ease: A Feasibility Pilot Study of an Arthritis Activity Intervention
Abstract Number: 2944

Longitudinal Outcomes and Predictors of E-Learning Effectiveness in Patients with Axial Spondyloarthritis: A Randomized Controlled Trial
Abstract Number: 2945

Culturally Enhanced Pain Coping Skills Training for African Americans with Osteoarthritis
Abstract Number: 2946

T Peripheral Helper Cells Are Expanded in the Circulation of Active SLE Patients and Correlate with CD21low B Cells
Abstract Number: 2947

Peripheral Helper T Cells in Systemic Lupus Erythematosus
Abstract Number: 2948

Deconstructing the in Situ Myeloid Cell Microenvironment in Human Lupus Nephritis Tissue
Abstract Number: 2949

African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways
Abstract Number: 2950

10X Genomics-Based Single-Cell RNA-Seq Analysis Identifies a Transcriptional Landscape of Inflammation and Fibrosis in Lupus Nephritis
Abstract Number: 2951

Ustekinumab Treatment Response in SLE Is Associated with Changes in Type II but Not Type I Interferons
Abstract Number: 2952

Major NSAID Toxicity: Derivation and Internal Validation of a Simple Clinical Risk Score
Abstract Number: 2953

Disappearance of Autoantibodies in RA: Does It Occur with Current Treatment Strategies? a Long-Term Follow-up Study in Patients That Achieved DMARD-Free Sustained Remission
Abstract Number: 2954

Factors Related to Initiation of TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
Abstract Number: 2955

Risk of Neurological Adverse Events during Tumour Necrosis Factor Inhibitor Treatment for Arthritis: A Population-Based Cohort Study from Danbio and the Danish National Patient Registry
Abstract Number: 2956

Changing Trends and Prescribing Patterns in Opioid-Treated Primary Care Patients with Non-Cancer Pain over a 10-Year Period

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].